Kaleido Biosciences Kapital društva 2024

Šta radi Kaleido Biosciences?

Kaleido Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of novel therapeutics for a variety of metabolic and immune disorders. The company, based in Lexington, Massachusetts, was founded in 2015 by David Berry, Michael Fischbach, Geoff von Maltzahn, and Noubar Afeyan. The founders brought together their expertise from various fields to develop a new class of drugs based on the manipulation of the microbial ecosystem in the human gut. The company has developed an innovative business model based on the Microbiome Metabolic Therapies (MMT) platform. This platform utilizes naturally occurring, non-pathogenic microorganisms to modulate specific metabolic pathways in the human body. By manipulating the microbiome, scientists at Kaleido Biosciences can influence specific disease states and develop new therapies for metabolic and immune system disorders. One of the areas of focus for the company is the treatment of various metabolic disorders, with a particular emphasis on regulating carbohydrate metabolism. Kaleido Biosciences uses the MMT platform to modify certain bacteria in the gut. The goal is to shift the balance of the gut flora in a way that promotes or suppresses specific metabolic reactions in the body. Another important area of focus is immunotherapy. The aim is to selectively influence the body's immune system to treat various disease states. Kaleido Biosciences is working on strategies to activate bacteria in the gut and trigger specific immune responses. In recent years, the company has developed several promising products and is currently in the clinical trial phase. One product is an MMT candidate for the treatment of celiac disease, an autoimmune disorder related to gluten digestion. Another product is an MMT candidate for the treatment of hyperammonemia in patients with ornithine transcarbamylase deficiency. Kaleido Biosciences also collaborates closely with various companies and partners to further develop its technology platform and identify new products. In 2018, the company entered into a strategic collaboration agreement with Pfizer to identify and develop a range of MMT candidates for the treatment of metabolic and immune disorders. Overall, Kaleido Biosciences Inc has made remarkable progress in a short period of time and developed an innovative technology platform for the development of new therapeutics for complex disease states. The company has quickly established a solid value creation community of investors, partners, and customers. With continued research efforts, partnership endeavors, and a customer-oriented approach, the future looks bright for Kaleido Biosciences. Kaleido Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.